ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0598

Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study

Adrienne Joseph, Brandon Windsor, Linda Hynan and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX

Meeting: ACR Convergence 2021

Keywords: Cutaneous, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Healthcare Disparities in Rheumatology Poster (0594–0622)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Epidemiological studies have shown that discoid lupus erythematosus (DLE) has a higher incidence and prevalence in minorities, particularly Black individuals. Racial differences in clinical features amongst DLE patients are not well understood. The objective of this retrospective cohort study was to examine the differences in DLE lesion distribution and characteristics of Black individuals compared to non-Black individuals.

Methods: Patients were recruited from the University of Texas Southwestern cutaneous lupus erythematosus (CLE) registry from January 2009 to June 2020. Adult DLE patients with a reported race/ethnicity and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores were included in this study. Patients were excluded if they had an additional CLE subtype, or if they were < 18 years old. DLE lesion locations and characteristics based on CLASI scores were the primary outcome variables. The primary predictor variable was race, which was categorized into Blacks and non-Blacks. Additional predictor variables included age at initial visit, gender, disease duration at initial visit, follow up duration, smoking status and presence or absence of SLE. SKINDEX-29+3 qualify of life scores were secondary outcome measures. Univariate analyses were performed to determine demographic differences and to compare lesion location, lesion characteristics, and quality of life scores between Black and non-Black patients. Multivariable logistic regression was performed to determine significant predictors of DLE lesion location.

Results: 183 DLE patients (112 Black and 71 non-Black) were included in this study. Black DLE patients had worse baseline CLASI damage scores compared to non-Black DLE patients (median: 10.0 (IQR: 6.0-14.5) vs. 6.0 (3.0-10.0), p< 0.001) (Table 1) and were more likely to have. In univariate analysis, Black patients were more likely to have scalp involvement [OR (95% CI): 2.54 (1.12-5.79), p=0.013] (Table 2). In multivariable analysis, Black patients had 2.54 (1.20-5.37) greater odds of having scalp involvement (p=0.015) and 1.97 (1.06-3.68) greater odds of having ear involvement (p=0.032) compared to non-Blacks. Black patients were more likely to have dyspigmentation (99% vs. 79%, p< 0.001) in any anatomical location), scalp (82% vs. 48%, p< 0.001), and ear (56% vs. 35%, p=0.006). They were also more likely to have scarring alopecia (79% vs. 56%, p=0.001) than non-Blacks (Table 3). No significant differences in SKINDEX-29+3 scores were seen between Black and non-Black patients with DLE.

Conclusion: Black DLE patients have important lesion location and characteristic differences compared to non-Black DLE patients. Signs of disease damage, particularly ear dyspigmentation, scalp dyspigmentation and scarring alopecia, can more frequently affect Black DLE patients and can help assist diagnosis and treatment plans. Our findings will help clinicians better understand racial differences in DLE presentation, which may lead to proper diagnosis and treatment initiation.

Table 1. Demographics and clinical characteristics of 112 Black and 71 non-Black DLE patients

Table 2. Univariate analyses of DLE lesion distribution based on CLASI scores in 112 Black and 71 non-Black patients

Table 3. Univariate analyses of DLE lesion characteristics based on CLASI scores in 112 Black and 71 Non-Black patients


Disclosures: A. Joseph, None; B. Windsor, None; L. Hynan, None; B. Chong, Daavlin Corporation, 5, Pfizer Incorporated, 12, Site PI for Clinical Trial, Amgen Incorporated, 12, Site PI for Clinical Trial, Biogen Incorporated, 12, Site PI for clinical trial, Viela Bio, 2, Beacon Bioscience, 2, Bristol Meyers Squibb, 1, EMD Serono, 2, Principia Biopharma, 2.

To cite this abstract in AMA style:

Joseph A, Windsor B, Hynan L, Chong B. Differences in Discoid Lupus Erythematosus Skin Lesion Distribution and Characteristics in Black and Non-Black Patients: A Retrospective Cohort Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/differences-in-discoid-lupus-erythematosus-skin-lesion-distribution-and-characteristics-in-black-and-non-black-patients-a-retrospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/differences-in-discoid-lupus-erythematosus-skin-lesion-distribution-and-characteristics-in-black-and-non-black-patients-a-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology